Athersys Inc. (NASDAQ: ATHX) has licensed its stem cell technology to a Florida firm that makes orthopedic implants in a deal that could be worth more than $40 million.
RTI Biologics Inc. plans to develop and commercialize implants based on Athersys’ Multipotent Adult Progenitor Cell (MAPC) technology, according to a statement from the companies. MAPC refers to a type of stem cells that can be differentiated into other types of cells.
“After significant research into stem cells and the evaluation of multiple technologies, we have determined that the MAPC technology offers the greatest potential to create high quality, innovative implants for our surgeons and their patients,” said Brian Hutchinson, RTI’s chief executive.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
The deal could be worth up to $40.5 million to Athersys. The terms of the agreement call for Athersys to receive a $3 million license fee and up to $37.5 million in payments that are contingent upon RTI hitting unspecified development and revenue milestones.
RTI hopes to begin selling implants developed from the Athersys technology in the first half of 2012.
Athersys’ proprietary MultiStem product also is based on MAPC technology. MultiStem is an off-the-shelf stem cell treatment derived from the bone marrow of adults or other non-embryonic sources. The cells have a drug-like effect: They reduce inflammation, protect damaged tissue and form new blood vessels, and then are cleared from the body.
In addition to the cash, the deal with RTI extends the application of Athersys’ technology to a new field — orthopedics. Athersys’ MultiStem product is being investigated for use in the treatment of cardiovascular, central nervous system-related, inflammatory and immune system disorders.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
News of the deal sent Athersys’ share price up about 2.5 percent to $3.02 in Monday morning trading.
